Viatris Inc. (VTRS)

11,16 -0,06 (-0,53%) Alla chiusura: 04:00PM EDT

Viatris Inc.

1000 Mylan Boulevard
Canonsburg, PA 15317
United States
724 514 1800
https://www.viatris.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 38.000

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Scott Andrew Smith	CEO & Director	5,07M	N/D	1962
Mr. Brian S. Roman	Chief Legal Officer	2,51M	N/D	1971
Ms. Theodora Mistras	Chief Financial Officer	N/D	N/D	1982
Mr. Paul B. Campbell	Chief Accounting Officer, Senior VP & Corporate Controller	N/D	N/D	1968
Mr. Ramkumar V. Rayapureddy	Chief Information Officer	N/D	N/D	N/D
Mr. Andrew Enrietti	Chief People Officer	N/D	N/D	N/D
Mr. Menassie Taddese M.B.A.	President of Emerging Markets	N/D	N/D	1970
Mr. Derek Glover	Chief Quality Officer	N/D	N/D	N/D
Ms. Lara Ramsburg	Chief Corporate Affairs Officer	N/D	N/D	N/D
Dr. Jeffrey Nau MMS, Ph.D.	President of Viatris Eye Care Division	N/D	N/D	1976

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Governance aziendale

L'ISS Governance QualityScore di Viatris Inc. al 1 maggio 2024 è 7. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 9; diritti degli azionisti: 6; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.